Table 1 Characteristics and clinical outcome in 200 IgAN patients receiving glucocorticoid medicine therapy

Baseline

 Age (years)

36.99 ± 11.33

36.20 ± 10.42

43.93 ± 16.34

 Gender: female, n (%)

113 (56.5)

100 (55.60)

13 (64.30)

 SBP (mm Hg)

124.33 ± 17.11

124.08 ± 16.08

126.43 ± 24.99

 DBP (mm Hg)

81.08 ± 11.10

81.33 ± 10.89

78.93 ± 13.04

 SCr (µmol/L)

89.2 (68.08–121.35)

88.25 (67.35–117.70)

108.95 (84.80–139.40)

 eGFR (mL/min/1.73 m²)

70.98 (51.91–95.93)

72.84 (52.93–96.39)

53.36 (46.55–62.35)

 BUN (mmol/L)

5.98 (4.60–7.80)

5.90 (4.60–7.40)

6.78 (5.46–8.94)

 UA (µmol/L)

363.00 (311.65–427.50)

359.00 (310.00–422.00)

380.50 (347.00–436.00)

 Hb (g/L)

131.00 (120.00–143.00)

132.50 (120.00–144.00)

124.00 (121.00–132.00)

 ALB (g/L)

38.20 (34.10–40.80)

38.40 (34.60–41.10)

33.75 (30.20–38.60)

 UPE (g/day)

2.27 (1.35–3.41)

2.14 (1.34–3.14)

3.08 (2.27–3.84)

 uRBC/HP

26.20 (8.03–67.48)

24.10 (7.80–66.55)

31.00 (12.30–51.70)

 CKD stage, n (%)

  Stage I

67 (33.5)

63 (35.0)

4 (20.0)

  Stage II

60 (30.0)

57 (31.6)

3 (15.0)

  Stage III

68 (34.0)

55 (30.6)

13 (65.0)

  Stage IV–V

5 (2.5)

5 (2.8)

0 (0)

  FSGS, n (%)

112 (56.0)

 Renal biopsy Lee’s classification, n (%)

  Grade I

4 (2.1)

3 (1.7)

1 (5.0)

  Grade II

4 (2.1)

2 (1.1)

2 (10.0)

  Grade III

115 (57.4)

103 (57.2)

12 (60.0)

  Grade IV

68 (34.0)

65 (36.1)

3 (15.0)

  Grade V

9 (4.3)

7 (3.9)

2 (10.0)

Follow-up

 Remission, n (%)

160 (80)

152(84.4)

8 (40.0)

 Complete remission, n (%)

71 (35.4)

68 (37.8)

3 (15.0)

 Partial remission, n (%)

89 (44.6)

84 (46.7)

5 (25.0)

 Non-response, n (%)

40 (20.0)

28 (15.6)

12 (60.0)

 Relapse, n (%)

35 (17.3)

24 (13.3)

11 (55.0)

 Progression, n (%)

20 (10)

 Length of follow-up (months)

68.33 (43.60–100.67)

67.33 (42.93–98.77)

71.42 (38.37–92.83)

 ALB (g/L) at month 3

39.45 (35.80–43.03)

40.00 (35.90–43.30)

37.50 (35.00–40.00)

 ALB (g/L) at month 6

41.50 (37.50–44.15)

42.20 (38.10–45.00)

36.75 (35.20–40.00)

 TA-ALB (g/L)

40.93 (38.05–44.14)

42.48 (38.75–44.65)

37.28 (36.40–39.01)

 SCr (µmol/L) at month 3

88.10 (71.60–105.00)

87.30 (71.60–104.80)

101.55 (78.80–112.20)

 SCr (µmol/L) at month 6

80.00 (64.70–104.50)

79.00 (64.70–100.60)

97.85 (78.00–128.50)

 TA-SCr (µmol/L)

85.24 (64.81–106.75)

83.73 (64.71–103.46)

99.34 (77.36–111.91)

 eGFR (mL/min/1.73 m²) at month 3

70.34 (56.97–98.72)

73.67 (58.04–98.72)

61.98 (48.87–81.43)

 eGFR (mL/min/1.73 m²) at month 6

80.02 (58.05–103.28)

81.08 (62.52–103.38)

58.68 (52.57–82.39)

 TA-eGFR (mL/min/1.73 m²)

76.93 (58.30–103.33)

80.61 (59.49–104.98)

58.74 (52.66–83.32)

 UPE (g/day) at month 3

0.79 (0.36–1.94)

0.73 (0.36–1.57)

1.26 (0.60–2.52)

 UPE (g/day) at month 6

0.63 (0.21–1.51)

0.60 (0.19–1.39)

1.36 (0.72–2.29)

 TA-UPE (g/day)

0.89 (0.51–1.75)

0.83 (0.49–1.69)

2.11 (0.82–2.36)